1. Scrip
  2. >>Focus On Asia

Korean Tagrisso Launch Builds On Extensive Local Data

 
• By Jung Won Shin

AstraZeneca's Tagrisso has debuted in South Korea, raising hopes and treatment options for certain types of lung cancer patients, but the product will face immediate local direct competition from Hanmi’s recently launched rival olmutinib.

SEOUL - South Korea has become the fifth market for AstraZeneca PLC's first-in-class lung cancer drug Tagrisso (osimertinib) after the US, Europe, Japan and Israel, following approval by the Ministry of Food and Drug Safety for EGFR T790M mutation-positive progressive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who have undergone EGFR-TKI therapy.

AstraZeneca Korea said the drug had been launched without reimbursement initially, but that it is seeking to apply for national...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV

 
• By Lisa Takagi

Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.

A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma

 
• By Jung Won Shin

Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.

GSK India Oncology Second Innings: Can Jemperli, Zejula Set The Pace?

 
• By Anju Ghangurde

GSK recommits to oncology in India with the debut of Jemperli and Zejula, backed by a tiered pricing approach, patient support program and efforts to address unmet needs in the biomarker ecosystem. Can it widen treatment access materially?

OneSource CEO On Next-Gen GLP-1 Innovator Talks, Xbrane And Viatris Partnering

 
• By Vibha Ravi

OneSource Specialty CEO Neeraj Sharma discusses with Scrip exploratory talks with next-gen GLP-1 innovators, prospects for semaglutide generics and investment in Swedish firm Xbrane, among other topics.

More from Scrip

Obesity Beyond GLP-1s: Myostatins – Too Important To Be Ignored?

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. After exploring the potential of amylin receptor agonists, we now look at myostatins, which analysts expect to generate peak sales of $30bn.

Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV

 
• By Lisa Takagi

Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.

A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma

 
• By Jung Won Shin

Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.